Research Roundup


Hypertension

Pharmacotherapy for hypertension, omega-3 for prevention of diabetes, SGLT2 inhibitors… Debbie Rigby rounds up the latest in research news

Pharmacotherapy for hypertension in adults 60 years or older

This is an updated Cochrane review of effects of antihypertensive drug treatment as compared with placebo or no treatment on all‐cause mortality in older persons with hypertension. Treating healthy adults 60 years or older with moderate to severe systolic and/or diastolic hypertension with antihypertensive drug therapy reduces all‐cause mortality, cardiovascular mortality and morbidity, cerebrovascular mortality and morbidity, and coronary heart disease mortality and morbidity.

Cochrane Database of Systematic Reviews 2019, Issue 6.

 

Omega-3, omega-6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus

A systematic review and meta-analysis of 83 randomised controlled trials suggests that increasing omega-3, omega-6, or total PUFA has little or no effect on prevention and treatment of type 2 diabetes mellitus. There was a suggestion that high dose supplementation (>4.4 g/d) with long chain omega-3 may worsen glucose metabolism. No evidence was found that the omega-3/omega-6 ratio is important for diabetes or glucose metabolism.

BMJ 2019;366:l4697.

 

Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases

Use of a fixed-dose combination therapy (polypill strategy) was effective in preventing major cardiovascular events in this cluster-randomised trial of 6838 participants aged 40-75 years. The polypill contained hydrochlorothiazide 12·5 mg, aspirin 81 mg, atorvastatin 20 mg, and enalapril 5 mg. Medication adherence was high (80%) and adverse event numbers were low. The authors concluded that the polypill strategy could be considered as an additional effective component in controlling cardiovascular diseases, especially in low-income and middle-income countries.

Lancet, published 24 August 2019.

 

Cardiovascular and Renal Benefits of SGLT2 Inhibitors

SGLT2 inhibitors have an important clinical advantage with improving glycemic control and cardiovascular and renal outcomes. This narrative review discusses the novel findings of the effects of SGLT2 inhibitors on cardiovascular and renal outcomes of type 2 diabetes.

Int J Endocrinol Metab. 2019 Apr; 17(2): e84353.

Previous Matching the hype
Next TWC joins with buy-now, pay-later ‘pioneer’

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.